Long and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of COVID-19.
Elnaz ShasebSaba GhaffaryAlireza GarjaniElnaz ZoghiNasrin Maleki DizajiSomaieh SoltaniParvin SarbakhshMohammad Hossein SomiParya ValizadehAli TaghizadiehMasood FaghihdinevariMojtaba VarshochiBehrooz NaghilyZhinous BayatmakooParviz SalehSepehr TaghizadehMehdi HaghdoostHamid OwaysiFatemeh Ravanbakhsh GhavghaniMohammad Kazem TarzamniRojin MoradiFateme Javan Ali AzarSaeid Shabestari KhiabaniArdavan GhazanchaeiSana HamedaniShahabeddin HatefiPublished in: Advanced pharmaceutical bulletin (2022)
In this trial, metformin consumption had no effect on mortality and ICU admission rates in non-diabetic patients. However, metformin improved COVID-19 complications in diabetic patients who had been receiving metformin prior to COVID-19 infection, and it significantly lowered the intubation rates.
Keyphrases
- randomized controlled trial
- coronavirus disease
- sars cov
- risk factors
- intensive care unit
- emergency department
- clinical trial
- type diabetes
- cardiac arrest
- stem cells
- cardiovascular disease
- risk assessment
- respiratory syndrome coronavirus
- coronary artery disease
- phase ii
- extracorporeal membrane oxygenation
- open label